Ignite Planners LLC Has $1.45 Million Holdings in Eli Lilly and Company $LLY

Ignite Planners LLC cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 6.3% during the 2nd quarter, Holdings Channel reports. The firm owned 1,872 shares of the company’s stock after selling 126 shares during the period. Ignite Planners LLC’s holdings in Eli Lilly and Company were worth $1,445,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Precedent Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after purchasing an additional 39 shares in the last quarter. Capital Advisors Inc. OK boosted its stake in Eli Lilly and Company by 6.8% in the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after buying an additional 429 shares in the last quarter. Family CFO Inc bought a new position in Eli Lilly and Company in the second quarter valued at about $54,000. Duquesne Family Office LLC grew its position in Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after acquiring an additional 32,640 shares during the last quarter. Finally, Corient IA LLC acquired a new position in Eli Lilly and Company during the first quarter worth about $570,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,022.00 on Friday. The company has a market capitalization of $966.19 billion, a price-to-earnings ratio of 66.80, a PEG ratio of 1.21 and a beta of 0.43. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,032.95. The stock has a fifty day simple moving average of $820.93 and a 200 day simple moving average of $779.85.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s revenue was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on LLY shares. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Finally, Loop Capital set a $950.00 target price on Eli Lilly and Company in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $999.32.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.